New Novus (300765.SZ): The application for clinical trials of the injectable SYS6040 drug has been approved by the US FDA

According to Zhitong Finance App, Xinover (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (“Jushi Biotech”), recently received a notice from the US Food and Drug Administration (hereinafter referred to as “FDA”) that the clinical trial application for injectable SYS6040 drugs declared by Jushi Biotech has been approved by the US FDA and can conduct clinical trials in the US.

According to reports, SYS6040 is a monoclonal antibody conjugate drug that binds to specific receptors on the surface of tumors to enter cells and release toxins through endocytosis to achieve the effect of killing tumor cells. The clinical indication approved this time is advanced solid tumors. Preclinical studies have shown that SYS6040 has shown good anti-tumor effects on various types of cancer and has high clinical development value. This product has submitted multiple patent applications at home and abroad.